Background Randomised trials have shown that aspirin reduces the short-term risk of
recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large …

Background High-dose aspirin (≥ 500 mg daily) reduces long-term incidence of colorectal
cancer, but adverse effects might limit its potential for long-term prevention. The long-term …

Background Long-term follow-up of randomised trials of aspirin in prevention of vascular
events showed that daily aspirin reduced the incidence of colorectal cancer and several …

Background Aspirin inhibits colorectal carcinogenesis. In a randomised double-blind
placebo-controlled trial, daily soluble aspirin significantly reduced recurrence of colorectal …

Considerable evidence supports the effectiveness of aspirin for chemoprevention of
colorectal cancer (CRC) in addition to its well-established benefits in the prevention of …

BACKGROUND & AIMS:: Epidemiologic and experimental studies have suggested that
aspirin intake reduces the risk for colorectal carcinogenesis. However, the available data are …

Using data from the population-based Prescription Database of North Jutland County and
the Danish Cancer Registry, we compared cancer incidence among 29 470 individuals …

Background Treatment with daily aspirin for 5 years or longer reduces subsequent risk of
colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of …

Background: Aspirin for prevention of colorectal cancer is controversial. Purpose: To
examine the benefits and harms of aspirin chemoprevention. Data Sources: MEDLINE, 1966 …

Use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a reduced
risk of colorectal cancer, but limited information is available on the effect of individual …